1. Scrip
  2. >>R&D

China CSCO Hails Rising Liver Cancer Innovation Ready To Take On World

China Transforming From Cancer Research Follower To Leader

 
• By Brian Yang

The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.

Jiangsu Hengrui Medicine
CHINA ONCOLOGY SOCIETY HAILS JIANGSU HENGRUI AS CHINA TAKES LEADERSHIP ROLE IN HCC DRUG DEVELOPMENT • Source: Shutterstock

The annual meeting of the Chinese Society of Clinical Oncology (CSCO) has become a prime venue for cancer drug makers and medical physicians to release their latest study results and provide outlook for potentially the largest oncology market in the world.

In its 23rd year, this year’s CSCO gathering, being held from 19-26 September and running in parallel to the European...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?